２０１４年　論文

 

原著論文（英文）

1.Takasu M, Tamura T, Kaichi Y, Tanitame K, Akiyama Y, Date S, Sakai A^*, Kuroda Y, Awai K. Magnetic resonance evaluation of multiple myeloma at 3.0 tesla: How do bone marrow plasma cell percentage and selection of protocols affect lesion conspicuity? Plos One. 9(1): e85931, 2014.

 

2.Zwick C, Held G, Auth M, Bernal-Mizrachi L , Roback JD, Sunay S, Iida S, Kuroda Y, Sakai A^*, Ziepert M, Ueda R, Pfreundschuh M , Preuss KD. Over one third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal-dominantly inherited risk factor for MGUS/MM. Int J Cancer. 135(4): 934-938, 2014.

 

3.Takasu M, Kaichi Y, Awai K, Asaoku H, Kuroda Y, Sakai A.*: Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis.Clin Lymphoma Myeloma Leuk. Feb;14(1): 12-13, 2014.

 

4.Takasu M, Tani C, Kaichi Y, Sakoda Y, Kiguchi M, Date S, Kuroda Y, Sakai A^*, Awai K. A longitudinal CT study of lenalidomide and bortezomib treatment for multiple myeloma: Trabeuclar microarchitecture and biomechanics assessed by a multidetector computed tomography. Clinical Lymphoma, Myeloma & Leukemia 14(6): 485-492, 2014.

 

5.Miura T, Nakata A, Kasai K, Nakano M, Abe Y^*, Tsushima E, Ossetrova NI, Yoshida MA, Blakely WF.A NOVEL PARAMETER, CELL-CYCLE PROGRESSION INDEX,FOR RADIATION DOSE ABSORBED ESTIMATION IN THE PREMATURE CHROMOSOME CONDENSATION ASSAY.Radiation Protection Dosimetry. 159(1-4): 52-60, 2014.

 

6.Sakai A^*, Ohira T, Hosoya M, Ohtsuru A, Satoh H, Kawasaki Y, Suzuki H, Takahashi A, Kobashi G, Ozasa K, Yasumura S, Yamashita S, Kamiya K, Abe M, for the Fukushima Health Management Survey Group. Life as an evacuee after the Fukushima Daiichi Nuclear Power Plant accident is a cause of polycythemia: The Fukushima Health Management Survey. BMC Public Health. 14;1318, 2014.

 

7.Kawasaki Y, Hosoya M, Yasumura S, Ohira T, Satoh H, Suzuki H, Sakai A^*, Ohtsuru A, Takahashi A, Ozasa K, Kobashi G, Kamiya K, Yamashita S, Abe M, and the Fukushima Health Management Survey Group: The Basic Data for residents aged 16 years or older who received a Comprehensive Health Check examinations in 2011-2012 as a part of the Fukushima Health Management Survey after the Great East Japan Earthquake. Fukushima J Med Sci. 60:159-169, 2014.

 

8.Sakai A*.Fukushima health management data: external radiation dose estimates. Fukushima J. Med.Sci.59(2) :110 ,2014.

 

9.Ohira T, Hosoya M, Yasumura S, Satoh H, Suzuki H, Takahashi A, Sakai A^*, Otsuru A, Kawasaki Y, Ozasa K, Kobashi G, Kamiya K, Yamashita S, Abe M.　How lifestyle affects health–changes in health status before and after the earthquake.　Fukushima J Med Sci. 2014;60(2):211-2.

 

 

総説（英文）

1.Sakai A^*, Yoshida N.The role of tumor-associated macrophages on serum soluble IL-2R level in B-cell lymphomas. J Clin and Exp Hematop. 54: 49-57, 2014.

 

 

原著論文（邦文）

1.神谷研二，稲葉俊哉，安村誠司，山下俊一，石川徹夫，大津留晶，坂井晃^*，鈴木眞一，細矢光亮，矢部博興，藤森敬也，阿部正文．福島原発事故による被ばく線量の概要とリスクコミュニケーション．長崎医会誌［特集：第55回原子爆弾後障害研究会講演集］89: 202-205, 2014.

 

2.福田俊章，石川和信，藤野美都子，坂井晃^*，挾間章博，岡田達也，志村清仁．医学セミナー　2013．福島医学雑誌　64(4): 211-212, 2014.

 

 

総説（邦文）

1.坂井晃^*，吉田稚明．悪性リンパ腫における血清中可溶性インターロイキン２レセプター（sIL-2R）に対する腫瘍関連マクロファージの役割．福島医学雑誌．64(2):67-75, 2014.

 

2.大津留晶，緑川早苗，志村浩己，坂井晃^*．東日本大震災から学ぶ内科疾患～特徴，対応，予防～6)放射線災害と内科学．日本内科学会雑誌．103(3)：581-587，2014.
3.津山尚宏^*．放射線量を見える化する生物学的分析法．BUNSEKI KAGAKU．63(6): 445-453, 2014.

 

4.坂井晃^*．電離放射線と血液がん．臨床血液．55(10): 338-345, 2014.

 

5.坂井晃^*．多発性骨髄腫 Updating 第7巻　再発・難治多発性骨髄腫 -再発の定義と再発例の治療目標-　VII　再発・難治多発性骨髄腫に対する第二世代の新規薬剤の効果　HDAC阻害剤　(2) Vorinostat．医薬ジャーナル社．7: 176-183, 2014.